The Structural Genomics Consortium Oxford is leading a new open-access platform to generate novel high-quality reproducible and renewable antibodies for both established and novel ALS genes and variants. Working in partnership with the ALS Association (US), the Motor Neurone Disease Association (UK) and the ALS Society of Canada, the SGC labs at the University of Oxford, Karolinska Institutet and Montreal Neurological Institute will jointly generate up to 75 novel renewable, fully validated high-quality antibodies for up to 45 novel ALS-associated genes (and variants). All the outputs will be made available IP-free and with complete freedom to operate. As per the SGC’s Open Science model, they are looking forward to engage with all the Oxford groups working on ALS and related research.
ALS Reproducible Antibody Platform launched
8 March 2018
Open Science to enable consistent data and accelerate reliable discoveries in Amyotrophic Lateral Sclerosis